Lauppe, R. et al. 2022. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study. Acta Oncologica. 61, 11 (Nov. 2022), 1354–1361. DOI:https://doi.org/10.1080/0284186X.2022.2133972.